COSCIENS Biopharma Inc.
CSCID evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CSCID—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CSCID
COSCIENS Biopharma Inc. is a biotechnology company focused on developing patented technologies and extracting active ingredients from natural sources, with ongoing insolvency proceedings for its German subsidiaries and a heavy reliance on a single distributor for revenue.
Key risk: German subsidiary insolvency
Market Cap
$5.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
COSCIENS Biopharma Inc. is a biotechnology company focused on developing patented technologies and extracting active ingredients from natural sources, with ongoing insolvency proceedings for its German subsidiaries and a heavy reliance on a single distributor for revenue.
- COSCIENS Biopharma is developing patented technologies and value-driving products, including extraction and commercialization of active ingredients from natural sources [sec · filed 2026-04-07].
- The company faces insolvency proceedings for its German subsidiaries, which could materially affect its operations and financial position [sec · filed 2026-04-07].
- As of December 31, 2025, COSCIENS reported total revenue of $1.8M, net income of -$2.2M, shareholders' equity of $13.2M, and total debt of $14.0M [latest reported financials].
- The company is heavily dependent on sales from its main distributor of active ingredients, creating concentration risk [sec · filed 2026-03-25].
- COSCIENS has no committed sources of capital and does not expect significant new revenues from operations in the near term, though it believes existing cash will fund operations for the next 12 months [sec · filed 2026-03-25].
What works
- COSCIENS holds patented technologies and value-driving products that are central to its business strategy [sec · filed 2026-04-07].
- The company is focused on extraction and commercialization of active ingredients from natural sources, a niche that may offer differentiation [sec · filed 2026-04-07].
What to weigh
- The company is subject to insolvency proceedings for its German subsidiaries, creating legal and financial uncertainty [sec · filed 2026-04-07].
- COSCIENS is heavily dependent on a single main distributor for active ingredient sales, posing a significant revenue concentration risk [sec · filed 2026-03-25].
- The company has no committed sources of capital and does not expect significant new revenues from operations in the near future, raising liquidity concerns [sec · filed 2026-03-25].
- Uncertainty in revenue generation from marketed products and potential failure of product development studies are key risks [sec · filed 2026-03-25].
From the filings
Quoted directly from source documents.
Insolvency proceedings for German subsidiaries
“the results of any insolvency proceedings in respect of the Company's German subsidiaries”
SEC filings · April 7, 2026
Dependence on main distributor
“our now heavy dependence on sales by and revenue from our main distributor of active ingredients and its customers”
SEC filings · March 25, 2026
No committed capital sources and near-term revenue uncertainty
“we currently have no committed sources of capital and do not currently expect to any significant new or additional sources of revenues from operations in the near future”
SEC filings · March 25, 2026
Risks & what to watch (4)›
Key risks
- German subsidiary insolvency — Insolvency proceedings for German subsidiaries could materially impact operations and financials [sec · filed 2026-04-07].
- Distributor concentration — Heavy reliance on one main distributor for active ingredient sales creates significant revenue risk [sec · filed 2026-03-25].
- Liquidity and capital access — No committed capital sources and no expected near-term revenue growth; cash may only last 12 months [sec · filed 2026-03-25].
- Product development uncertainty — Products under development may not succeed or support advancement, impacting future pipeline [sec · filed 2026-03-25].
What to watch
- Outcome of insolvency proceedings for German subsidiaries and their legal/accounting implications [sec · filed 2026-04-07].
- Ability to secure additional financing or partnerships given lack of committed capital sources [sec · filed 2026-03-25].
- Revenue trends and dependency on the main distributor for active ingredients [sec · filed 2026-03-25].
- Progress of product development and validation studies for pipeline candidates [sec · filed 2026-03-25].
Sources: SEC filings · Generated August 26, 2026 · How we verify sources →
Run COSCIENS Biopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available COSCIENS Biopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2025Institutional holders
2
Total value held
$10K
| Holder | Shares | Value |
|---|---|---|
| td waterhouse canada inc. | 3,860 | $10K |
| osaic holdings, inc. | 50 | $153 |
Short Interest
as of May 20, 2026- % of float
- 0.3%
- Days to cover
- 0.6
- Shares short
- 8,244
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CSCID short interestFrequently asked questions
What is the AI investment thesis for COSCIENS Biopharma Inc.?
COSCIENS Biopharma Inc. is a biotechnology company focused on developing patented technologies and extracting active ingredients from natural sources, with ongoing insolvency proceedings for its German subsidiaries and a heavy reliance on a single distributor for revenue.
Who is the CEO of COSCIENS Biopharma Inc.?
Mr. Peter Harry Puccetti CFA is the chief executive officer of COSCIENS Biopharma Inc. (CSCID).
Where is COSCIENS Biopharma Inc. headquartered?
COSCIENS Biopharma Inc. (CSCID) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.